TO THE EDITOR
The incidence of childhood ALL in the European Union countries and the USA 1,2 peaks between 1 and 5 years of age, most cases being of common ALL phenotype. Good prognostic features of B-lineage ALL include hyperdiploidy with DNA index Ͼ1.16 Ͻ1.6, low leukocyte count and low presenting age. Age between 1 and 5 years at diagnosis is currently considered by the BFM (Berlin-Frankfurt-Mü nster) group as an indicator of favorable prognosis provided that negative prognostic factors are absent (these include poor response to prednisone induction treatment, T lineage or mature B cell leukemia immunophenotypes, leukocyte count equal to 20 × 10 9 /l or higher, BCR/ABL or MLL/AF4 fusion genes) (treatment protocol ALL BFM95).
The age criterion has been disputed by Rubnitz and Pui 3 who advocated the use of molecular genetic analysis, ie identification of BCR/ABL, E2A/PBX1, TEL/AML1 fusion genes and MLL rearrangements rather than age and leukocyte count for the initial risk group assignment. Most recently the TEL/AML1 hybrid gene, which is the product of t(12;21)(p12;q22) translocation, has been recognised as an independent positive prognostic factor in pediatric ALL. 4, 5 As described previously, [4] [5] [6] most TEL/AML1-positive children are diagnosed before 10 years of age; here we show their age distribution in more detail.
In order to study the occurrence of t(12;21)-positive cases in childhood ALL in the Czech Republic, we established a reverse-transcriptase polymerase chain reaction (RT-PCR)-based method for the detection of hybrid TEL/AML1 mRNA. We studied bone marrow (BM) and/or peripheral blood (PB) samples from 167 unselected patients with ALL younger than 18 years, newly diagnosed between March 1995 and January 1998. Samples were successfully analyzed by RT-PCR in 165 cases, quality of cDNA in two samples was inadequate for analysis. Seven patients presented with other fusion genes, BCR/ABL (n = 3) or MLL/AF4 (n = 4), respectively. All patients were treated according to ALL BFM90 or 95 protocols (excluding two MLL/AF4-negative, TEL/AML1-negative and one MLL/AF4-positive infants treated according to POG protocol No. 9407) in one of the Pediatric Hematology Working Group (PHWG) centers. Since all centers in the Czech Republic that have been treating children with ALL from 1995 to 1998 are united in PHWG, our data refer to virtually all patients diagnosed in our country during this period. RT-PCR analysis was performed using the 'nested-PCR' approach, as described elsewhere. 6 All patients' specimens were analyzed using flow cytometry and a panel of monoclonal antibodies following the recommendation of BFM protocols ALL BFM90 or ALL BFM95. Patients classified as proB ALL, common ALL and preB ALL are categorized as B cell precursor (BCP) ALL, patients with mature B ALL or T-lineage ALL were categorized as non-BCP ALL. Throughout this study, age 1 refers to age у1 year and Ͻ2 years at diagnosis and correspondingly in all other age groups.
Thirty-seven of 165 patients available for analysis were TEL/AML1-positive (22.4%). Thus, we confirmed previous observations demonstrating that TEL/AML1 fusion is the most frequent genetic abnormality in childhood ALL. When considering only B cell precursor ALL (144 patients), the relative frequency of TEL/AML1 fusion is 25.7%, which is similar to 22-28% reported in the previous studies. [4] [5] [6] All our 21 non-BCP patients were TEL/AML1-negative, similarly as reported previously. 4 The age distribution in our cohort of patients is shown in Figure 1 . In contrast to previously published studies which showed one peak in the age distribution of childhood ALL, 2 two peaks are found in our cohort with medians at 3 and 12 years, respectively. The existence of the second peak corresponds to a higher proportion of older children within our cohort: 30% of patients 10 years and older at diagnosis, compared to less than 20% found in other studies. 2, 4 The previously mentioned studies [4] [5] [6] stated the age of the vast majority of TEL/AML1-positive children was between 1 and 10 years. The incidence of the TEL/AML1 hybrid gene among ALL patients older than 10 years and among adults is rare. The detailed analysis of the age distribution of our TEL/AML1-positive cohort displayed the concentration of these cases to the age group of 2 to 4 years (P Ͻ 0.0001; Hines and Montgomery, 7 this test does not presume normal distribution in the compared sets of data). Seventy-eight percent (29/37) of all our TEL/AML1-positive patients come under the interval of 2 to 4 years of age (Figure 2) . However, TEL/AML1-negative patients still accumulate in this age although a lower proportion of these patients is in the first peak (Figure 3) . Thus,
Figure 1
Age distribution of ALL patients at diagnosis. The age at presentation (n = 165 patients) is shown according to the type of ALL. Black columns represent patients with BCP ALL; white columns, non-BCP ALL. Bimodal distribution is apparent among BCP patients as well as in the whole cohort.
Figure 2
Age distribution of TEL/AML1-positive ALL at diagnosis. All TEL/AML1-positive patients had BCP ALL phenotype.
Figure 3
Age distribution of TEL/AML1-negative BCP ALL at diagnosis.
the peak of ALL between 1 and 5 years is only partly formed by TEL/AML1-positive cases. This was revealed by recalculation of the data presented in previous studies, 4 as well as in our cohort of patients in which the age peak of TEL/AML1-positive ALL seems to be narrower than previously reported by other groups. Nevertheless, we suppose that thorough comparison of the age distribution of both TEL/AML1-positive and TEL/AML1-negative cases within the large cohorts of patients is required. Only this type of analysis could eventually reveal whether our results are valid generally or whether the peak of TEL/AML1 positives extends to higher age in other populations.
Recently, BFM group questioned the positive prognostic value of TEL/AML1. 8 However, better event-free survival of TEL/AML1-positive patients has reached a significant level in our cohort (P Ͻ 0.05, median follow-up 13 months), as previously documented by others. 4, 5 This obviously represents a short-term prognostic importance of TEL/AML1 positivity since relapses occur only later than 24 months after diagnosis in TEL/AML1-positive patients. 8 In conclusion, we show that the majority of TEL/AML1-positive patients (78.4%) accumulate at the age of 2-4 years and we document in the Figures that the distribution of the TEL/AML1-positive patients appears to be Gaussian. This accumulation of the TEL/AML1-positive patients allows us to hypothesize that beside hyperdiploidy, TEL/AML1 positivity contributes to a better prognosis of this particular age group.
